Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6350089

CONC(=O)[C@@H](N)Cc1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.51
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
PTGS1 P23219 1/20 0.51
XIAP P98170 1/20 0.51
CTRB1 P17538 3/20 0.50
CTSC P53634 1/20 0.49
SLC15A1 P46059 1/20 0.49
OPRK1 P41145 6/20 0.47
LTA4H P09960 1/20 0.47
PTPN1 P18031 1/20 0.46
GRB2 P62993 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27512979 0.92 SLC7A5 (0.59) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL27512978 0.92 SLC7A5 (0.59) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL6165004 0.91 SLC7A5 (0.58) SLC7A5ALPIPKMPTGS1XIAP
Trifluoroacetic Acid SCHEMBL8849659 0.85 ALPI (0.51) SLC7A5ALPIPKMPTGS1XIAP
Trifluoroacetic Acid SCHEMBL6967778 0.85 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine Methyl Ester SCHEMBL28593408 0.85 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Trifluoroacetic Acid SCHEMBL7268667 0.85 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Trifluoroacetic Acid SCHEMBL11579813 0.82 OPRK1 (0.62) CTSCOPRK1
Trifluoroacetic Acid SCHEMBL13519233 0.82 OPRK1 (0.53) SLC7A5ALPIPKMPTGS1XIAP
Trifluoroacetic Acid SCHEMBL13519232 0.82 OPRK1 (0.53) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 SLC7A5 387/4885ALPI 269/4885PKM 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.